Theseus Pharmaceuticals

Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Theseus Pharmaceuticals is a technology-based company.

-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- CAMBRIDGE, Mass. , Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that Concentra Biosciences, LLC ("Concentra") through its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4.05 in cash (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per share (each, a "CVR" and each CVR together with the Cash Amount, the "Offer Price") representing the right to receive 80% of the net proceeds from any license or disposition of certain of Theseus' programs effected within 180 days of the close of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of the merger, pursuant to a Contingent Value Rights Agreement.

Theseus Pharmaceuticals Announces Closing of Tender Offer

SAN DIEGO--(BUSINESS WIRE)--As previously announced on December 22, 2023, Concentra Biosciences, LLC (“Parent”) and its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Purchaser”), entered into a merger agreement (the “Merger Agreement”) with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) (“Theseus”) whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 pe.

Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals

NEW ORLEANS , Jan. 22, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Theseus Pharmaceuticals, Inc. (NasdaqGS: THRX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Theseus will receive between $3.90 and $4.05 in cash for each share of Theseus that they own. KSF is seeking to determine whether this consideration and the process that le.

THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX

Theseus Pharmaceuticals (THRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?

MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Theseus (NASDAQ: THRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join the https://www.ademilaw.com/case/theseus-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Theseus Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Concentra

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) to Concentra Biosciences, LLC for between $3.90 and $4.05 in cash is fair to Theseus shareholders. Halper Sadeh encourages Theseus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation con.

THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to Shareholders

CAMBRIDGE, Mass. , Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ("Concentra") will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") of between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of not more than $0.15 per share at the closing of the merger (together with the Base Price, the "Cash Amount"), plus one non-tradeable contingent value right ("CVR") representing the right to receive 80% of the net proceeds from any license or disposition of Theseus' programs effected within 180 days of closing of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of the merger, pursuant to a Contingent Value Rights Agreement (the "CVR Agreement").

Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right

Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.

Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan

CAMBRIDGE, Mass. , Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Company not already owned by Foresite or OrbiMed in a going-private transaction.

Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC

CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it is conducting a process exploring strategic alternatives to maximize shareholder value.

Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives

CAMBRIDGE, Mass. , Nov. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that the company will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14 at 9:45 a.m.

Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference

Theseus Pharmaceuticals experienced significant losses after discontinuing its lead program, leaving it with a market cap of half of its current assets. THRX is now focusing on developing a fourth-generation EGFR inhibitor for the treatment of EGFR-mutated non-small cell lung cancer. The company has enough funds to sustain operations until 2026, but the success of its pipeline drugs remains uncertain.

Theseus Pharmaceuticals: Picking Up The Pieces After A Lead Failure

The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024 Nomination of highly selective pan-variant KIT inhibitor candidate for GIST expected in H1 2024 Announces plans to explore the development of low dose THE-630 in mast cell-driven inflammatory indications based on dose-dependent reductions in serum tryptase levels in patients in GIST study $234.2 million of cash, cash equivalents, and marketable securities as of June 30, 2023 CAMBRIDGE, Mass. , Aug. 10, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the second quarter ended June 30, 2023.

Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results

After Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)

Aadi Bioscience

FibroGen

Inogen

Silk Road Medical Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me

Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.

Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study

Theseus Pharmaceuticals (NASDAQ: THRX ) stock is falling hard on Friday after the company announced poor results from a Phase 1/2 clinical trial. According to a press release from Theseus Pharmaceuticals, the company is no longer enrolling patients in its clinical trial for THE-630 in patients with gastrointestinal stromal tumors (GIST).

Why Is Theseus Pharmaceuticals (THRX) Stock Down 68% Today?

ACADIA Pharma

Stock markets kept climbing on Thursday. Acadia stock moved higher as the company expanded a key licensing agreement.

Why These 2 Biotech Stocks Made Big Moves Late Thursday

Theseus Pharmaceuticals Inc. THRX, -3.74% shares plummeted after hours Thursday after the biotech drug maker discontinued enrolling patients in the study of a cancer drug it no longer intend to develop. Theseus shares plunged as much as 75% in the extended session Thursday, following a 3.7% decline to close the regular session at $9.52.

Theseus Pharmaceuticals stock plummets after cancer drug development stopped

-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR inhibitor for EGFR mutant non-small cell lung cancer; IND on track for submission in Q4 2023 -- -- Theseus announces new program targeting KIT for patients with early-line GIST; development candidate nomination expected in the H1 2024 -- -- Development candidate nomination from BCR-ABL program also expected in H1 2024 -- -- $234 million in cash, cash equivalents, and marketable securities as of June 30, 2023; runway extended into 2026 -- CAMBRIDGE, Mass. , July 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it is discontinuing enrollment in the ongoing phase 1/2 study and terminating development of THE-630 in patients with gastrointestinal stromal tumors (GIST).

Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST

CAMBRIDGE, Mass. , May 31, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in a live Fireside Chat at the Jefferies Healthcare Conference on June 8 th at 10:30am ET.

Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference

-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both major classes of KIT resistance mutations at exposures consistent with preclinical predictions observed in Predictive Resistance Assay™ -- -- Evidence of clinical activity observed in heavily pre-treated patient population at exposures below target, with 8 out of 9 evaluable patients treated in Cohorts 4-6 (9 to 18 mg) achieving stable disease -- -- Dose escalation ongoing to achieve target exposure of 100 nM predicted for pan-variant KIT activity, projected in Cohort 8 (40 mg) -- -- Company to host virtual investor event today at 5:30pm ET -- CAMBRIDGE, Mass. , May 25, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced gastrointestinal stromal tumors (GIST).

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

-- THE-630 initial dose escalation data to be presented at investor event on May 25, 2023, with additional dose escalation data expected in Q4 2023 -- -- IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023; development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected by early 2024 -- -- $243.6 million of cash, cash equivalents, and marketable securities as of March 31, 2023, with runway projected into Q3 2025 -- CAMBRIDGE, Mass. , May 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the first quarter ended March 31, 2023.

News for Theseus Pharmaceuticals Stock (THRX)